Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891693 | 0.88 | PIK3CD (0.47) | PIK3CDSCN9AATMS1PR1 | |
| SCHEMBL4169782 | 0.86 | SCN9A (0.43) | PIK3CDSCN9A | |
| SCHEMBL4173906 | 0.85 | PIK3CD (0.58) | PIK3CDATMS1PR1 | |
| SCHEMBL1883936 | 0.82 | PIK3CD (0.47) | PIK3CDATM | |
| SCHEMBL1887556 | 0.82 | PIK3CD (0.53) | PIK3CDATM | |
| SCHEMBL1598353 | 0.82 | PIK3CD (0.57) | PIK3CDATM | |
| SCHEMBL1598116 | 0.80 | PIK3CD (0.49) | PIK3CDATM | |
| SCHEMBL1885178 | 0.79 | ATM (0.45) | PIK3CDSCN9AATMS1PR1 | |
| SCHEMBL1884713 | 0.79 | PIK3CD (0.46) | PIK3CDS1PR1 | |
| SCHEMBL1878618 | 0.79 | ATM (0.52) | PIK3CDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2231641-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | PIK3CD 8/4885SCN9A 1908/4885ATM 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.